FDA Rejects Ivonescimab Filing Over Evidence Portability

FDA issued a complete response letter for Summit’s ivonescimab plus chemotherapy application in EGFR-mutant non-small-cell lung cancer after EGFR-targeted treatment. The public letter says substantial evidence of effectiveness and a favorable benefit–risk profile were…




